预测新生儿阿片类药物戒断综合征患者对吗啡治疗反应的异质性
Daniel Smolyak1, Elizabeth M Humphries2,3, Abhinav Parikh4
1Department of Computer Science, University of Maryland, College Park, Maryland, USA.
Clinical pharmacology and therapeutics
|July 20, 2023
概括
使用芬尼根新生儿禁欲评分系统 (FNASS) 评分和多基因风险评分 (PRS) 的早期婴儿监测可以帮助预测新生儿阿片类药物戒断综合征治疗反应. 这有助于临床医生量身定制吗啡治疗或替代疗法,以获得更好的婴儿结果.
科学领域:
- 新生儿戒断综合征 新生儿戒断综合征
- 药物基因组学 药物基因组学
- 临床信息学 临床信息学
背景情况:
- 新生儿阿片类药物戒断综合征 (NOWS) 婴儿通常接受吗啡以治疗症状,但治疗效果各不相同.
- 预测个体婴儿对吗啡的反应对于优化护理至关重要.
研究的目的:
- 确定早期婴儿监测数据,包括修改的芬尼根新生儿禁欲评分系统 (FNASS) 评分和阿片类药物依赖的多基因风险评分 (PRS),是否可以预测NOWS中对吗啡治疗的反应.
- 探索早期临床评分,遗传风险,药物暴露和住院结果之间的关系.
主要方法:
- 基于早期的FNASS分数 (12小时治疗开始前和后) 使用K-means集群对213名婴儿进行了分组.
- 基于树的机器学习方法构建了网络图形,以可视化FNASS分数,PRS,药物暴露和住院结果之间的关系.
- 统计分析比较了确定的婴儿群体的风险因素和结果.
主要成果:
- 三个不同的婴儿群体出现了,在风险因素 (例如,甲暴露) 和住院结果 (例如,总接收的吗啡,住院时间) 中显著不同.
- 多基因风险评分 (PRS) 不能预测接受治疗,但在某些婴儿群体之间显示出显著差异.
- 网络分析显示,早期FNASS分数,PRS和随后的住院结果之间存在有意义的联系.
结论:
- 早期的FNASS分数和PRS为预测婴儿对NOWS药物治疗的个体反应提供了宝贵的见解.
- 这些发现可以使临床医生能够个性化治疗策略,可能涉及早期或替代干预.
- 整合预测数据可以改善新生儿阿片类药物戒断综合征的婴儿的临床决策.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
338
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
338
Analgesia and Pain Management
661
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
661
Opioid Analgesics: Morphine and Other Natural Cogeners
293
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
293
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Opioid Receptors: Overview
1.1K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.1K
Analysis of Population Pharmacokinetic Data
297
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
297


